Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2001

View Archived Issues

Canadian neuroprotection research collaboration announced

NDA submission for King's injectable estrogen replacement therapy

Positive results obtained in phase II trial of phenserine in Alzheimer's patients

Axcan to acquire Enteris

Amersham Health to develop and market Bexxar in Europe

Ribi-529 adjuvant added to Corixa/Wyeth Lederle Vaccines license agreement

Lilly receives approvable letter from FDA for Xigris

Preclinical and clinical data for Tularik's lead anti-HCMV agent discussed at IDSA

Human pharmacokinetic/drug interaction and resistance data reported at IDSA for ABT-773

BMS-284756 preclinical and clinical results a highlight of the IDSA meeting

Ariad continues to strengthen product pipeline

Celebrex indications expanded with recent FDA approval

Medivir summarizes clinical and preclinical project progress

Interim findings from single-dose human trial support further clinical evaluation of MDX-010

Development of antipsychotic 5-HT2A inverse agonist initiated by Acadia

Dual topoisomerase I and II inhibitor shows promise for colon cancer

MTD not reached in ongoing phase I trials of PKI-166, an EGF receptor tyrosine kinase inhibitor

Company Profile: Biovitrum

New tablet formulations of linezolid claimed by Pharmacia

Tanox designs anticomplement monoclonal antibodies for autoimmune and inflammatory diseases

New indoles acting as DP receptor antagonists in the Ono pipeline

Gastric prokinetic agents with a hydroxyethoxybenzamide structure synthesized at Kissei

Kuraray patents new compounds for use in breast cancer

Baxter acquires Asta Medica Oncology

European mutual recognition procedure completed for Estradot

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...